A panel of experts met to discuss the best treatment options for patients with EGFR or TP53-mutated non-small cell lung cancer. A Satellite Session hosted in Seattle, WA, focused on various treatment options that would best benefit a patient with EFGR and TP53 mutated non-small cell lung cancer. The panel mainly focused on osimertinib (Tagrisso) or Lazertinib (Lazcluze) plus amivantamab-vmjw (Rybrevant) and how those would be the best options to help treat that specific patient.